Moshinsky Deborah J, Bellamacina Cornelia R, Boisvert David C, Huang Ping, Hui Terence, Jancarik Jaru, Kim Sung-Hou, Rice Audie G
SUGEN, Inc., South San Francisco, CA 94080, USA.
Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31. doi: 10.1016/j.bbrc.2003.09.114.
SU9516 is a 3-substituted indolinone compound with demonstrated potent and selective inhibition toward cyclin dependent kinases (cdks). Here, we describe the kinetic characterization of this inhibition with respect to cdk2, 1, and 4, along with the crystal structure in complex with cdk2. The molecule is competitive with respect to ATP for cdk2/cyclin A, with a K(i) value of 0.031 microM. Similarly, SU9516 inhibits cdk2/cyclin E and cdk1/cyclin B1 in an ATP-competitive manner, although at a 2- to 8-fold reduced potency. In contrast, the compound exhibited non-competitive inhibition with respect to ATP toward cdk4/cyclin D1, with a 45-fold reduced potency. The X-ray crystal structure of SU9516 bound to cdk2 revealed interactions between the molecule and Leu83 and Glu81 of the kinase. This study should aid in the development of more potent and selective cdk inhibitors for potential therapeutic agents.
SU9516是一种3-取代吲哚酮化合物,已证明对细胞周期蛋白依赖性激酶(cdks)具有强效和选择性抑制作用。在此,我们描述了该抑制剂对cdk2、1和4的抑制动力学特征,以及与cdk2形成复合物的晶体结构。该分子在cdk2/细胞周期蛋白A中对ATP具有竞争性,K(i)值为0.031微摩尔。同样,SU9516以ATP竞争性方式抑制cdk2/细胞周期蛋白E和cdk1/细胞周期蛋白B1,尽管效力降低了2至8倍。相比之下,该化合物对cdk4/细胞周期蛋白D1表现出对ATP的非竞争性抑制,效力降低了45倍。与cdk2结合的SU9516的X射线晶体结构揭示了该分子与激酶的Leu83和Glu81之间的相互作用。这项研究应有助于开发更有效和选择性的cdk抑制剂作为潜在治疗药物。